Hiperprolaktinemide total antioksidan düzey: bromokriptin tedavisinin etkileri

Abstract

Objective: The aims of the study were to evaluate i) total antioxidant status (TAS) in women with hyperprolactinemia ii) whether bromocriptine had an antioxidant property in that group of patients. Materials and Methods: Twenty-four hyperprolactinemic women and 20 healthy control group were enrolled in the study. Blood samples were collected from the study and control groups during the folucular phase. Blood samples were collected again from hyperprolactinemic women on bromocriptine therapy after 8 weeks. FSH, LH, estradiol (E2), prolactin and TAS were measured. Results: Serum LH, E2 and TAS levels were significantly lower and prolactin was significantly higher in hiperprolactinemic women than in controls. Serum FSH levels did not differ between the groups. There were no significant differences in FSH, LH andE2 levels after bromocriptine use in hyperprolactinemic women. However, after treatment with bromocriptine the patients demonstrated significant increase in TAS and significant decrease in prolactin levels. Discussion: In this study, we demonstrated that TAS levels were significantly lower in patients with hyperprolactinemia and bromocriptine had protective effect with its antioxidant capacity. It is not only a very effective agent for lowering prolactin levels in hyperprolactinemic patients, but also increases antioxidant activity in that group of patients.